Compare Abbott Laboratories (ABT) vs Hormel Foods Corp (HRL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Hormel Foods Corp — how do they compare? Abbott Laboratories trades at $95.6 (market cap $166.94B), while Hormel Foods Corp trades at $24.5 (market cap $13.59B). The key difference: Abbott Laboratories is far larger — about 12.3× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (4.74%). Which is the better fit depends on your goals.
| ABT | HRL | |
|---|---|---|
Market Cap | $166.94B | $13.59B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $31.54 |
52-Week Low | $82.57 | $19.74 |
Enterprise Value | $193.69B | $15.59B |
Dividend Yield | 2.63% | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Hormel Foods (HRL) trades at $24.70, down 1.2% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The stock has consistently beaten earnings estimates in recent quarters, though net income margin has compressed to 3.82%. Recent corporate actions include steady $0.29 dividends, while the company sold its Brazilian Ceratti operations to sharpen international focus. Analyst consensus price target is $25.00, slightly above current levels.
HRL offers a stable dividend profile as a Dividend King but faces margin pressure and modest growth. Near-term upside appears limited given current valuation and mixed analyst ratings. Key risks include input cost inflation and competitive pressures in the consumer staples sector. The stock presents a defensive income opportunity rather than significant capital appreciation potential in the current environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
